Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals (RYTM)
:RYTM
RESEARCH TOOLSreports
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.69Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 7.60%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong financial positioning, robust sales growth, and significant pipeline advancements. However, there are concerns about high operating expenses and potential challenges in market uptake for new indications.Company Guidance
During the Rhythm Pharmaceuticals earnings call, the company provided several key metrics and guidance for the upcoming year. They reported entering 2025 well-capitalized with $320.6 million in cash, aided by a $75 million raise through their ATM program, extending their cash runway into 2027. The company completed enrollment in their Phase II daily oral bivamelagon study and achieved a dropout rate of below 10% in their Phase III trial of setmelanotide for acquired hypothalamic obesity (HO), with a second quarter 2025 readout expected. Revenue from global IMCIVREE sales reached $130.1 million in 2024, a significant increase from $77.4 million in 2023, with consistent growth in both the U.S. and international markets. Rhythm anticipates non-GAAP operating expenses for 2025 to be between $285 million and $315 million, with increased spending due to expansion plans and ongoing trials. The company also highlighted strategic partnerships, particularly in Turkey, to expand market reach, and emphasized the potential for growth in Japan, where the prevalence of hypothalamic obesity is higher than in the U.S. or Europe.Strong Financial Position
Rhythm Pharmaceuticals raised $75 million in gross proceeds, extending their cash run rate into 2027, allowing them to fund operations through multiple inflection points.
Positive Growth in IMCIVREE Sales
U.S. sales of IMCIVREE were $31.7 million in Q4 2024, accounting for 76% of the quarter's revenue, marking a significant growth compared to previous periods.
Expansion of International Access
IMCIVREE has achieved access in more than 15 countries outside the U.S., contributing to steady growth in international markets.
Pipeline Advancements
Enrollment completed for Phase II oral bivamelagon study; Phase III trial of setmelanotide in acquired HO with a second-quarter readout expected.
FDA Label Expansion for IMCIVREE
The FDA approved a label expansion for IMCIVREE to include children as young as 2 years of age, broadening its applicability and potential impact.
---
RYTM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RYTM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $51.03 | $53.32 | +4.49% |
| Nov 05, 2024 | $56.25 | $62.65 | +11.38% |
| Aug 06, 2024 | $44.03 | $44.04 | +0.02% |
| May 07, 2024 | $43.88 | $39.35 | -10.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Rhythm Pharmaceuticals (RYTM) report earnings?
Rhythm Pharmaceuticals (RYTM) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Rhythm Pharmaceuticals (RYTM) earnings time?
Rhythm Pharmaceuticals (RYTM) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RYTM EPS forecast?
RYTM EPS forecast for the fiscal quarter 2024 (Q4) is -0.69.
---